Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Capital Leases (2024 - 2025)

Vanda Pharmaceuticals' Capital Leases history spans 2 years, with the latest figure at $4.1 million for Q4 2025.

  • For Q4 2025, Capital Leases rose 29.56% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $4.1 million, up 29.56%, while the annual FY2025 figure was $4.1 million, 29.56% up from the prior year.
  • Capital Leases for Q4 2025 was $4.1 million at Vanda Pharmaceuticals, up from $2.8 million in the prior quarter.
  • Across five years, Capital Leases topped out at $4.1 million in Q4 2025 and bottomed at $2.8 million in Q3 2025.